Sulfonanilide Derivatives in Identifying Novel Aromatase Inhibitors by Applying Docking, Virtual Screening, and MD Simulations Studies

BioMed Research International - Tập 2017 - Trang 1-17 - 2017
Shailima Rampogu1, Minky Son1, Chanin Park1, Hyong-Ha Kim2, Jung-Keun Suh3, Keun Woo Lee1
1Division of Applied Life Science (BK21 Plus), Plant Molecular Biology and Biotechnology Research Center (PMBBRC), Systems and Synthetic Agrobiotech Center (SSAC), Research Institute of Natural Science (RINS), Gyeongsang National University (GNU), 501 Jinju-daero, Jinju 52828, Republic of Korea
2Division of Quality of Life, Korea Research Institute of Standards and Science, Daejeon 34113, Republic of Korea
3Bio-Computing Major, Korean German Institute of Technology, Seoul 07582, Republic of Korea

Tóm tắt

Breast cancer is one of the leading causes of death noticed in women across the world. Of late the most successful treatments rendered are the use of aromatase inhibitors (AIs). In the current study, a two-way approach for the identification of novel leads has been adapted. 81 chemical compounds were assessed to understand their potentiality against aromatase along with the four known drugs. Docking was performed employing the CDOCKER protocol available on the Discovery Studio (DS v4.5). Exemestane has displayed a higher dock score among the known drug candidates and is labeled as reference. Out of 81 ligands 14 have exhibited higher dock scores than the reference. In the second approach, these 14 compounds were utilized for the generation of the pharmacophore. The validated four-featured pharmacophore was then allowed to screen Chembridge database and the potential Hits were obtained after subjecting them to Lipinski’s rule of five and the ADMET properties. Subsequently, the acquired 3,050 Hits were escalated to molecular docking utilizing GOLD v5.0. Finally, the obtained Hits were consequently represented to be ideal lead candidates that were escalated to the MD simulations and binding free energy calculations. Additionally, the gene-disease association was performed to delineate the associated disease caused by CYP19A1.

Từ khóa


Tài liệu tham khảo

10.1021/jm701107h

10.1186/s40200-015-0138-1

10.1155/2014/390618

10.1158/2159-8290.CD-11-0101

10.3892/or.2014.3190

10.2174/138920206779315737

10.2174/1574884711308020006

10.1074/jbc.M305226200

2003, Clinical Cancer Research, 9, 524S

10.1111/j.1742-1241.2007.01587.x

10.1007/s11606-009-1037-2

10.1038/bjc.2011.58

10.1634/theoncologist.2008-0055

10.1016/j.ejmech.2015.08.010

10.1016/0960-0760(92)90198-R

10.1210/me.2006-0281

10.1186/s40199-014-0083-4

10.1016/j.bmc.2015.04.036

10.1155/2016/6068437

10.1038/nature07614

10.7150/ijms.5344

10.3390/molecules19056609

10.3390/ijms16022747

10.1021/acsami.5b06617

10.1002/jcc.20291

10.1016/0010-4655(95)00042-E

10.1007/S008940100045

10.1002/jcc.21816

10.1063/1.328693

10.1002/jcc.540130805

10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H

10.1063/1.464397

10.1016/0263-7855(96)00018-5

10.1021/ci500020m

10.1073/pnas.181342398

10.1002/minf.201100135

10.1021/ar000033j

10.1093/nar/gkw943

10.1093/database/bav028

10.1038/msb.2008.27

10.1038/nbt.1487

10.1093/bfgp/elr024

10.1155/2015/130620

1991, Clinical Pharmacology & Therapeutics, 50

10.1377/hlthaff.25.2.420

10.2147/DDDT.S108118

10.1186/1423-0127-18-8

10.1602/neurorx.2.4.541

10.1134/S0026893308040195

10.1155/2014/364819

10.1080/10799893.2016.1212376

10.1016/j.compbiomed.2016.06.005

10.1016/j.bpj.2011.03.052

10.1007/s12010-016-2207-4

10.1021/ct4007037

10.4238/vol10-3gmr1204

10.1371/journal.pone.0040262

10.1038/nrd2199

10.1371/journal.pone.0150460

10.1007/s13311-014-0325-7

10.1093/bib/bbs043

Thông tin
Thông tin xuất bản

BioMed Research International

Tập 2017

1-17

Thông tin tác giả